AddedRisk Factors
•the prevalence and severity of side effects associated with any of our future products;
Read it in 10-K Feb 26, 2026 at sec.govopen_in_new
AddedRisk Factors
•the convenience and ease of administration of our future products relative to alternative therapies, if any;
Read it in 10-K Feb 26, 2026 at sec.govopen_in_new
AddedRisk Factors
•our inability or delay in gaining or maintaining reimbursement and broad patient access at a price that reflects the value of our future products;
Read it in 10-K Feb 26, 2026 at sec.govopen_in_new
AddedRisk Factors
•our inability to address product labeling or product insert requirements, including any changes mandated by regulatory authorities after initial approval;
Read it in 10-K Feb 26, 2026 at sec.govopen_in_new
RemovedRisk Factors
We have no marketed proprietary products and have not yet completed clinical development beyond Phase 2 clinical trials, which makes it difficult to assess our ability to develop our future product candidates and commercialize any resulting products independently.
Read it in 10-K Feb 27, 2025 at sec.govopen_in_new
RemovedRisk Factors
•changes in tariffs, trade barriers and regulatory requirements including as a result of trade relations between Canada and the United States;
Read it in 10-K Feb 27, 2025 at sec.govopen_in_new
RemovedRisk Factors
For example, in 2010, the Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act of 2010, collectively, the PPACA, was enacted and includes measures that have significantly changed the way healthcare is financed by both governmental and private insurers. Beyond the ACA, there are ongoing and widespread healthcare reform efforts, a number of which have focused on regulation of prices or payment for drug products. Drug pricing and payment reform was a focus of the first Trump administration and the Biden administration. For example, federal legislation eliminated a statutory cap on Medicaid drug rebate program rebates effective January 1, 2024. As another example, the Inflation Reduction Act (IRA) of 2022 includes a number of changes intended to address rising prescription drug prices in Medicare Parts B and D. These changes, which have varying implementation dates, include caps on Medicare Part D out-of-pocket costs, Medicare Part B and Part D drug price inflation rebates, a new Medicare Part D manufacturer discount drug program (replacing the PPACA Medicare Part D coverage gap discount program) and a drug price negotiation program for certain high-spend Medicare Part B and D drugs. The IRA is likely to have a significant impact on the pharmaceutical industry as implementation proceeds. As another example, in 2022, subsequent to the enactment of the IRA, the Biden administration announced its commitment to expanding certain IRA reforms. Drug pricing and payment reform was a focus of the prior Trump administration and that focus is likely to continue under the new Trump administration. Other potential healthcare reform efforts under the Trump administration may affect access to healthcare coverage or the funding of health care benefits. There is significant uncertainty regarding the nature or impact of any such reform implemented by the Trump administration through executive action or by Congress. Further, a number of states have enacted state drug price transparency and reporting laws that could substantially increase our compliance burdens and expose us to greater liability under such state laws if and when we have marketed products. These and other health reform measures that are implemented may have a material adverse effect on our operations.
Read it in 10-K Feb 27, 2025 at sec.govopen_in_new
RemovedRisk Factors
Healthcare reform efforts have been and may continue to be subject to scrutiny and legal challenge. For example, with respect to the PPACA, tax reform legislation was enacted that eliminated the tax penalty established for individuals who do not maintain mandated health insurance coverage beginning in 2019 and, in 2021, the U.S. Supreme Court dismissed the latest judicial challenge to the ACA brought by several states without specifically ruling on the constitutionality of the PPACA. As another example, revisions to regulations under the federal anti-kickback statute would remove protection for traditional Medicare Part D discounts offered by pharmaceutical manufacturers to pharmacy benefit managers and health plans. Pursuant to court order, the removal was delayed and recent legislation imposed a moratorium on implementation of the rule until January 2032. As another example, the IRA drug price negotiation program has been challenged in litigation filed by various pharmaceutical manufacturers and industry groups.
Read it in 10-K Feb 27, 2025 at sec.govopen_in_new
RewordedRisk Factors
Such authorities suspensions or terminations may impose such arise from a suspension or termination due to a number variety of factors, including failure to conduct the clinical trial study in accordance with regulatory requirements or our clinical protocols, inspection of the clinical trial operations or trial site by the FDA, EMA or other foreign regulatory authorities resulting in the inspections, imposition of a clinical hold, product candidate manufacturing problems, unforeseen safety issues or adverse side effects, failure to demonstrate a benefit from using a drug, lack of demonstrated benefit, changes in governmental regulations or administrative actions or lack of adequate insufficient funding to continue the clinical trial. study.
Read it in 10-K Feb 26, 2026 at sec.govopen_in_new
RewordedRisk Factors
A statutory instrument to amend the Medicines for Human Use (Clinical Trials) Regulations 2004 was laid before parliament The new regulations will take full effect on December 12, 2024, and will come into force in early April 10, 2026 after a 12-month implementation period to address the research sector’s need for a more efficient, streamlined and adaptable regulatory framework for clinical trials. studies.
Read it in 10-K Feb 26, 2026 at sec.govopen_in_new
RewordedRisk Factors
Any challenges associated with Difficulties in identifying, screening and/or enrolling patients in our trials studies may extend the time needed to complete our clinical trials studies or require the initiation of additional sites to be initiated in order to achieve target enrollment numbers and to complete our clinical trials, which may increase the cost of our operations and/or delay the timing of our regulatory approval. studies.
Read it in 10-K Feb 26, 2026 at sec.govopen_in_new
RewordedRisk Factors
A statutory instrument to amend the Medicines for Human Use (Clinical Trials) Regulations 2004 was laid before parliament on December 12, 2024, and will come into force in early 2026 after a 12-month implementation period to address the research sector’s need for a more efficient, streamlined and adaptable regulatory framework for clinical trials. 2024.
Read it in 10-K Feb 26, 2026 at sec.govopen_in_new
RewordedRisk Factors
The current conflicts Current and future global conflicts, such as those between Ukraine and Russia and in the Middle East, as well as recent failures have created, and may in the global banking sector, have created future create, volatility in the capital markets and are expected to may have further global economic consequences.
Read it in 10-K Feb 26, 2026 at sec.govopen_in_new
RewordedRisk Factors
Although the CCPA exempts these state consumer data and consumer health data privacy laws generally exempt some data processed in the context of clinical trials, the CCPA, studies, to the extent they are applicable to in our business and operations, these laws may increase compliance costs and potential liability with respect to other personal information we maintain about California residents. residents of these states.
Read it in 10-K Feb 26, 2026 at sec.govopen_in_new
RewordedRisk Factors
In addition, Outside of the SEC and applicable United States, Canadian securities regulators regularly pursue various rulemaking efforts, including recently efforts with respect to environmental, social ESG matters, which has resulted in the adoption of new laws and governance, or ESG, matters. regulations.
Read it in 10-K Feb 26, 2026 at sec.govopen_in_new
RewordedRisk Factors
Efforts to ensure that our activities comply with applicable healthcare laws and regulations will involve substantial costs. costs and, if and when one of our product candidates is approved, our compliance efforts will need to expand and evolve to address newly applicable laws.
Read it in 10-K Feb 26, 2026 at sec.govopen_in_new
RewordedRisk Factors
This law imposes In addition, several states have enacted health-focused consumer privacy laws, such as Washington state's My Health, My Data Act, which impose obligations related to the collection and sharing of certain health-related information that is not subject to HIPAA and that does not fall within certain other exceptions in the law.
Read it in 10-K Feb 26, 2026 at sec.govopen_in_new
RewordedRisk Factors
In addition, our ability to compete may be affected by decisions made by insurers or other third-party payers. payers or public health systems to secure favorable coverage and reimbursement as well as the commercial success of our product candidates.
Read it in 10-K Feb 26, 2026 at sec.govopen_in_new
RewordedRisk Factors
In addition, the information we choose to publicly disclose regarding a particular study or clinical trial is based on what is typically extensive complex body of information, and you or others may not agree with our determination of what we determine is constitutes material or otherwise appropriate information to include in our for disclosure.
Read it in 10-K Feb 26, 2026 at sec.govopen_in_new
RewordedRisk Factors
We had net losses of $345.9 million, $234.3 million, $182.4 million and $125.4 $182.4 million for the years ended December 31, 2024, 2023 2025, 2024 and 2022, 2023, respectively, and an accumulated deficit of $899.5 $1,245.4 million as of December 31, 2024, 2025, which were driven by expenses incurred in connection with our research and development programs and from general and administrative costs associated with our operations.
Read it in 10-K Feb 26, 2026 at sec.govopen_in_new
Quiet changesRisk Factors
Our commercial success will depend, in part, on our ability to obtain and maintain patent, trademark and trade secret protection of our product candidates and future products, their respective components, formulations, methods used to manufacture them and methods of treatment, as well as successfully defending against possible third-party challenges.
Read it in 10-K Feb 26, 2026 at sec.govopen_in_new
Quiet changesRisk Factors
Many of our directors and officers reside outside of the U.S., and all or a substantial portion of their assets as well as all or a substantial portion of our assets are located outside the U.S.
Read it in 10-K Feb 26, 2026 at sec.govopen_in_new
AddedMD&A
•Topline data from the Phase 3 X-TOLE2 study of azetukalner in FOS is on track for the first half of March 2026.
Read it in 10-K Feb 26, 2026 at sec.govopen_in_new
AddedMD&A
•Phase 3 X-TOLE3 study of azetukalner in FOS continues to enroll and is intended to support regulatory submissions outside the United States. We have completed an ethnobridging study and shared results with Japan’s Pharmaceutical and Medical Devices Agency, or PMDA. We aligned with PMDA to enroll approximately 60 of the planned 360 X-TOLE3 participants in Japan to support a potential regulatory submission in Japan. X-TOLE3 enrollment outside of Japan is expected to complete in 2026.
Read it in 10-K Feb 26, 2026 at sec.govopen_in_new
AddedMD&A
•We presented 48-month data from the X-TOLE OLE study at the American Epilepsy Society, or AES, annual meeting, reinforcing the long-term efficacy and safety of azetukalner with more than 775 patient-years of exposure data in the OLE. Among participants treated for ≥48 months, reductions in monthly FOS frequency were over 90% from double-blind period baseline, with over 38% achieving at least 12 months of seizure freedom.
Read it in 10-K Feb 26, 2026 at sec.govopen_in_new
AddedMD&A
•Phase 3 X-CEED study evaluating azetukalner in patients with BPD I or II is underway.
Read it in 10-K Feb 26, 2026 at sec.govopen_in_new
AddedMD&A
We continue to expand our portfolio of innovative potassium and sodium channel modulators. Nav1.7 and Kv7 are important targets for pain and have been developed using our strong heritage in human genetics, deep understanding of ion channel biology, and expertise in novel chemistries to design potent, selective ion channel modulators.
Read it in 10-K Feb 26, 2026 at sec.govopen_in_new
AddedMD&A
•Phase 1 SAD/MAD study in healthy adult participants is underway for XEN1701 targeting Nav1.7. Study completion is expected in 2026 to support initiating a Phase 2 proof-of-concept study in acute pain.
Read it in 10-K Feb 26, 2026 at sec.govopen_in_new
AddedMD&A
•Phase 1 SAD/MAD study in healthy adult participants is underway for XEN1120 targeting Kv7. Study completion is expected in 2026 to support initiating a Phase 2 proof-of-concept study in acute pain.
Read it in 10-K Feb 26, 2026 at sec.govopen_in_new
AddedMD&A
We recognize external research and development costs for research and development activities conducted by third-party service providers, which include the conduct of pre-clinical studies and clinical studies, and manufacturing activities. When determining the research and development expense, we use information and data provided by our vendors and third-party service providers. This process involves reviewing open contracts, communicating with applicable vendors and third-party service providers to identify services that have been performed, estimating the level of service performed and the associated cost incurred for the service when we have not yet been invoiced or otherwise notified of actual costs.
Read it in 10-K Feb 26, 2026 at sec.govopen_in_new
RemovedMD&A
•Phase 3 X-TOLE2/3 azetukalner clinical studies in FOS continue to advance, with the first topline data readout anticipated in the second half of 2025.
Read it in 10-K Feb 27, 2025 at sec.govopen_in_new
RemovedMD&A
•Building upon more than 700+ patient-years of data to date from the ongoing X-TOLE open-label extension, or OLE, study, we continue to generate long-term scientific evidence supporting azetukalner’s compelling efficacy and safety profile, with approximately one in three patients on drug for at least 36 months achieving seizure freedom for a period of one year or longer.
Read it in 10-K Feb 27, 2025 at sec.govopen_in_new
RemovedMD&A
•We recently announced plans for a Phase 3 BPD program with initiation of the first of two azetukalner clinical studies in bipolar I and bipolar II depression expected by mid-year. Initiation of this program is based on a strong scientific rationale – supported by promising clinical data with azetukalner and the Kv7 mechanism in MDD and preclinical research examining the genetic links between BPD and Kv7 and evidence of Kv7 downregulation in BPD – as well as a large unmet medical need.
Read it in 10-K Feb 27, 2025 at sec.govopen_in_new
RemovedMD&A
•Patient enrollment in the investigator-sponsored Phase 2 proof-of-concept study of azetukalner in MDD led by Icahn School of Medicine at Mount Sinai is complete, and topline results are anticipated in the first half of 2025.
Read it in 10-K Feb 27, 2025 at sec.govopen_in_new
RemovedMD&A
We continue to expand our portfolio by leveraging our extensive expertise to discover and develop potassium and sodium channel therapeutics, with the goal of filing multiple INDs, or equivalent, in 2025.
Read it in 10-K Feb 27, 2025 at sec.govopen_in_new
RemovedMD&A
•IND-enabling work is underway with multiple Kv7 development candidates. Kv7 may have utility in a broad range of therapeutic indications including seizures, pain, and neuropsychiatric disorders, such as MDD and BPD.
Read it in 10-K Feb 27, 2025 at sec.govopen_in_new
RemovedMD&A
•IND-enabling work is underway with a lead Nav1.7 development candidate. Nav1.7 is an important pain-related target, based on strong human genetic validation, that may represent a new class of medicines without the limitations of opioids.
Read it in 10-K Feb 27, 2025 at sec.govopen_in_new
RemovedMD&A
Year Ended December 31, 2024 2023 2022 Recognition of the transaction price $ $ $ 372 Research and development services 1,938 Milestone payments 7,124 Total revenue $ $ $ 9,434
Read it in 10-K Feb 27, 2025 at sec.govopen_in_new
RemovedMD&A
Pursuant to the terms of the Neurocrine Collaboration, we received an upfront cash payment of $30.0 million and a $20.0 million equity investment in our common shares in December 2019. The overall transaction price of the arrangement was measured and allocated to certain performance obligations and revenue was recognized as those performance obligations were completed. In January 2022, based on the U.S. Food and Drug Administration’s (“FDA”) approval to expand the SCN8A-DEE study population to include subjects aged between 2 and 11 years, we received an aggregate milestone payment of $15.0 million in the form of $6.75 million cash and $8.25 million equity investment in our common shares. The equity investment was measured at fair value on the date of issuance and the resulting premium with the cash payment, was recognized as revenue. Research and development services were recognized as revenue at fair market value as the services were rendered. The research collaboration was completed in June 2022.
Read it in 10-K Feb 27, 2025 at sec.govopen_in_new
RemovedMD&A
Our primary sources of revenue are derived from non-refundable upfront payments, funding for research and development services, milestone payments, and royalties under license and collaboration agreements.
Read it in 10-K Feb 27, 2025 at sec.govopen_in_new
RemovedMD&A
In contracts where we have more than one performance obligation to provide our customer with goods or services, each performance obligation is evaluated to determine whether it is distinct. The consideration under the contract is then allocated between the distinct performance obligations based on their respective relative standalone selling prices. The estimated standalone selling price of each deliverable reflects our best estimate of what the selling price would be if the deliverable was regularly sold on a standalone basis and is determined by reference to market rates for the good or service when sold to others or by using an adjusted market assessment approach if selling price on a standalone basis is not available.
Read it in 10-K Feb 27, 2025 at sec.govopen_in_new
RemovedMD&A
The consideration allocated to each distinct performance obligation is recognized as revenue when control is transferred to our customer for the related goods or services. We generally recognize revenue from non-refundable upfront payments over the estimated term of the performance obligation or period in which the underlying benefit is transferred to our customer. If non-refundable license fees have value to the customer on a standalone basis, separate from the undelivered performance obligations, they are recognized upon delivery. We evaluate the measure of progress each reporting period and, if necessary, adjust the measure of performance and related revenue recognition. Consideration in exchange for research and development services performed by us on behalf of the licensee is recognized upon performance of such activities at rates consistent with prevailing market rates. Consideration associated with at-risk substantive performance milestones, including sales-based milestones, is recognized as revenue using the most likely amount method when it is probable that a significant reversal of the cumulative revenue recognized will not occur. At the end of each subsequent reporting period, we re-evaluate the probability of achievement of such milestones, and if necessary, adjust the estimate of the overall transaction price. Sales-based royalties received in connection with licenses of intellectual property are subject to a specific exception in the revenue standards, whereby the consideration is not included in the transaction price and recognized in revenue until the customer’s subsequent sales or usages occur.
Read it in 10-K Feb 27, 2025 at sec.govopen_in_new
RewordedMD&A
Azetukalner, a novel, highly potent, selective potent Kv7 potassium channel opener, represents the most advanced, clinically validated clinically-validated potassium channel modulator in late-stage clinical development for the treatment of multiple indications that include epilepsy, indications, including focal onset seizures, or FOS, two in epilepsy – FOS and primary generalized tonic-clonic seizures, or PGTCS, PGTCS – as well as neuropsychiatric disorders disorders, including major depressive disorder, or MDD and bipolar depression, or BPD.
Read it in 10-K Feb 26, 2026 at sec.govopen_in_new
RewordedMD&A
Personnel-related costs increased by $16.1 $4.6 million for the year ended December 31, 2025, primarily due to higher headcount to support our expanding research and development activities and future potential commercialization as well as an increase commercialization, partially offset by a decrease in stock-based compensation expense due to an increase in the number of options granted at a higher fair value. and recruitment costs.
Read it in 10-K Feb 26, 2026 at sec.govopen_in_new
RewordedMD&A
Pre-clinical Pre-clinical, discovery and discovery other program costs increased decreased by $6.0 $4.0 million due to our decision in May 2023 to no longer pursue the clinical development of XEN496, partially offset by increase in costs due to the advancement of multiple potential drug candidates targeting Kv7, Nav1.7 and Nav1.1.
Read it in 10-K Feb 26, 2026 at sec.govopen_in_new
RewordedMD&A
Personnel-related costs increased by $22.9 $19.8 million driven by an increase in due to higher headcount to support late-stage product candidate development and an increase in stock-based compensation expense due to an increase in the number of options granted at a higher fair value. expense.
Read it in 10-K Feb 26, 2026 at sec.govopen_in_new
RewordedMD&A
As of December 31, 2024, 2025, an aggregate of 310,000 2,961,023 common shares have been sold for proceeds of $12.1 $124.2 million, net of commissions and transaction expenses. expenses, of which $112.2 million, net of commissions and transaction expense. were raised during the three months ended December 31, 2025.
Read it in 10-K Feb 26, 2026 at sec.govopen_in_new
RewordedMD&A
Compensation expense for PSUs is recognized if the performance condition is considered probable of achievement using our best estimates and is amortized on a straight-line basis over the requisite service period of each separately vesting tranche of the award. estimates.
Read it in 10-K Feb 26, 2026 at sec.govopen_in_new
RewordedMD&A
Professional and consulting fees increased by $5.4 $4.3 million primarily due to an increase in pre-commercial expenses, partially offset by lower legal costs associated with legal services in support of our ongoing business operations and pre-commercial activities.
Read it in 10-K Feb 26, 2026 at sec.govopen_in_new
RewordedMD&A
We did not recognize any revenue in the years ended December 31, 2024 and 2023, as compared to recognized revenue from collaboration agreements of $9.4 $7.5 million for the year ended December 31, 2022. 2025.
Read it in 10-K Feb 26, 2026 at sec.govopen_in_new
RewordedMD&A
The change was driven primarily by an increase a decrease in the redemption purchase of marketable securities, net of purchases. redemptions, as well as a decrease in the purchases of property, plant and equipment.
Read it in 10-K Feb 26, 2026 at sec.govopen_in_new
RewordedMD&A
We did not recognize any revenue in the years ended December 31, 2024 and 2023, as compared to revenue from collaboration agreements of $9.4 million for the year ended December 31, 2022. 2023.
Read it in 10-K Feb 26, 2026 at sec.govopen_in_new
RewordedMD&A
Interest income increased decreased by $18.9 $15.1 million for the year ended December 31, 2025, driven by a higher lower average balance of marketable securities and an increase in lower average market yields on investments.
Read it in 10-K Feb 26, 2026 at sec.govopen_in_new
RewordedMD&A
The increase was primarily related to net proceeds from the issuance of $353.5 common shares of $112.2 million in 2023 2025 as compared to net proceeds of $277.8 $12.1 million in 2022 2024 from the issuance of common shares and pre-funded warrants. shares.
Read it in 10-K Feb 26, 2026 at sec.govopen_in_new